SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : Pharmos(PARS)
PARS 2.700+13.6%Jan 21 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Zvi Steinberg who wrote (1288)9/26/1998 9:31:00 PM
From: Zvi Steinberg  Read Replies (1) of 1491
 
Congress of Neurosurgeons, Seattle, Washington - Pharmos to present
results of the first two cohorts of dexanabinol (HU-211) for the Phase
II clinical trials for severe head trauma. On October 7, Nachshon
Knoller to make the presentation entitled, "Safety and Outcome in a
Phase II Clinical Trial of Dexanabinol in Severe Head Trauma."
pharmoscorp.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News